- Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
- Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
- Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
- Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
More ▼
Key statistics
On Friday, Silo Pharma Inc (SILO:NAQ) closed at 1.10, 5.08% above its 52-week low of 1.05, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.26 |
---|---|
High | 1.26 |
Low | 1.06 |
Bid | 1.11 |
Offer | 1.12 |
Previous close | 1.21 |
Average volume | 527.12k |
---|---|
Shares outstanding | 3.69m |
Free float | 3.51m |
P/E (TTM) | -- |
Market cap | 4.06m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 20:59 BST.
More ▼